Evidence map›Paper›PMID 39453468›Full record

Observational studyAesthetic plastic surgery2025

Autologous Micrografts Containing Nanovesicles, Exosomes, and Follicle Stem Cells in Androgenetic Alopecia: In Vitro and In Vivo Analysis Through a Multicentric, Observational, Evaluator-Blinded Study.

Pietro Gentile, Simone Garcovich, Franco Perego, Nazneen Arsiwala, Mehmet Faruk Yavuz, Valeria Pessei, Tommaso Pusceddu, Barbara Zavan, Shenaz Arsiwala

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pietro GentilePlastic and Reconstructive Surgery, Department of Surgical Science, "Tor Vergata" University, 00133, Rome, Italy. pietrogentile2004@libero.it.ORCID 0000-0003-3123-3977
Simone GarcovichCERSID - Dermatology Outpatient Services, Rome, Italy.
Franco PeregoSchool of Plastic, Reconstructive and Aesthetic Surgery, University of Padua, Padua, Italy.
Nazneen ArsiwalaRenewderm Skin Hair Laser Aesthetics Centre and Masina Hospital Mumbai, Mumbai, India.
Mehmet Faruk YavuzMehmet Faruk Yavuz Clinic, Beşiktaş, İstanbul, Turkey.
Valeria PesseiDepartment Chemistry, Biology, Biotechnology, University of Perugia, Perugia, Italy.
Tommaso PuscedduDepartment Translational Medicine, University of Ferrara, 44121, Ferrara, Italy.
Barbara ZavanDepartment Translational Medicine, University of Ferrara, 44121, Ferrara, Italy.
Shenaz ArsiwalaRenewderm Skin Hair Laser Aesthetics Centre and Saifee Hospital, Masina Hospital Mumbai, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of micrografts (MCGs) containing human follicle mesenchymal stem cells (HF-MSCs) is a hair loss (HL) treatment that needs to be standardized as seems to have promising effects on hair regrowth (HR-G) also thanks to the presence of extracellular vesicles (EVs).

objectivesThe study aims to report both the in vivo results, obtained in patients affected by androgenic alopecia (AGA) treated using MCGs, and in vitro analysis characterizing the EVs.

methodsA multicentric, retrospective, observational, evaluator-blinded study was conducted. Eighty-three AGA patients were initially enrolled [52 suffering from male pattern hair loss (MPHL) at stages I-III vertex by the Norwood-Hamilton scale and 31 suffering from female PHL (FPHL) at stages I-II by the Ludwig scale]. Sixty patients (20 females and 40 males) were treated and analyzed after exclusion and inclusion criteria assessment. The in vivo HR-G was evaluated through photography, physician's, and patient's global assessment scales, in addition to standardized photo-trichograms, during a follow-up for 1 year, while the in vitro analysis was performed through a quantitative, morphological, and dimensional characterization of the EVs population using transmission electron microscopy (TEM) and fluorescent microscopy.

resultsA hair density (HD) increase of 28 ± 4 hairs/cm

conclusionsMCGs containing HF-MSCs and exosomes may fill in as a safe and viable alternative treatment against HL in mild and moderate degrees of AGA both in MPHL and in FPHL. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 .

Indexed as

AlopeciaExosomesHair FollicleMesenchymal Stem Cell TransplantationAdultCells, CulturedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSingle-Blind MethodTransplantation, AutologousTreatment OutcomeYoung AdultAndrogenetic alopeciaExosomes hairsHair lossMicrograftsPlastic surgeryRegenerative plastic surgery

Identifiers

PMID39453468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.